Changing fortunes: Is biotech giant CSL’s $10b write-down a comeback story?
Make no mistake: the home-grown biotechnology company, which for decades allowed Australia serious boasting rights, is still a long way from redemption.
5News aggregated this summary from the outlet’s public feed. The full article, with all the context, is on www.smh.com.au — the content belongs to Sydney Morning Herald - Business.
